Part ofHHS Budget →

FEDERALhearing transcript

High Impact

Senate Hearing on the 2022 HHS Budget Proposal

Original title: THE PRESIDENT'S FISCAL YEAR 2022 HHS BUDGET

January 1, 2023

HHS Budget Prescription Drug Pricing Medicare Mental Health Alzheimer's Treatment Healthcare Transparency

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

The Frame

What this does

This hearing sets the legislative agenda for federal health spending and policy priorities, including potential changes to Medicare drug negotiation authority and the implementation of the .

Who is mentioned in the record

Potentially affected actors named in the source documents. Mention is not a position.

Medicare recipients

Proposed changes to drug negotiation authority and the expansion of the CHRONIC Care Act directly impact the costs and services available to over 50 million seniors.

Department of Health and Human Services

The agency's funding and policy priorities for the 2022 fiscal year are determined by the budget process discussed in this hearing.

What changed

Last recorded activity January 1, 2023.

What's next

Next step not available in the current record.

Summary

The Senate Finance Committee held a hearing on June 10, 2021, to review the President's proposed 2022 budget for the Department of Health and Human Services (HHS). Secretary Xavier Becerra testified before the committee, which focused on rising prescription drug costs, mental health initiatives, and Medicare policy.

Key Facts

The hearing reviewed the President's Fiscal Year 2022 budget proposal for the Department of Health and Human Services.
Chairman Wyden highlighted concerns regarding the $56,000 annual list price of the Alzheimer's drug Aduhelm.
The committee discussed granting Medicare the authority to negotiate prescription drug prices.
The administration proposed new initiatives regarding mental health care.
The committee is working on further implementation of the 2018 CHRONIC Care Act to expand benefits for traditional Medicare recipients.
The administration is continuing efforts to increase transparency in health-care pricing for consumers.

Why It Matters

This hearing sets the legislative agenda for federal health spending and policy priorities, including potential changes to Medicare drug negotiation authority and the implementation of the .

Frequently Asked Questions

What was the primary purpose of this hearing?

To discuss and review the President's proposed 2022 budget for the Department of Health and Human Services with Secretary Xavier Becerra.

What specific drug pricing concerns were raised?

Chairman Wyden expressed concern over the $56,000 annual cost of the new Alzheimer's drug, Aduhelm, and advocated for Medicare to have the power to negotiate drug prices.

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Discoveries

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

policy shift90% confidence

Focus on Drug Pricing

The hearing demonstrates a clear legislative push to link the HHS budget process with aggressive reforms to Medicare drug pricing authority.

Ron Wyden Department of Health and Human Services

Connected Entities

personRon Wyden“Chairman of the Senate Finance Committee”Map →

otherAduhelm“Alzheimer's medication discussed regarding its $56,000 annual price”Map →

personXavier Becerra“Secretary of the Department of Health and Human Services”Map →

organizationDepartment of Health and Human Services“The federal department whose budget was under review”Map →

personMike Crapo“Ranking member of the Senate Finance Committee”Map →

organizationSenate Finance Committee“The committee conducting the hearing”Map →

Sources

Open source document

www.govinfo.gov

Analysis Score

0–100

Significance85
How much this matters to a regular citizen
Controversy60
Intensity of disagreement among stakeholders
Entertainment20
Compellingness for a non-policy-wonk reader
Buzz30
Current news / social attention level

Publisher tools